Please provide your email address to receive an email when new articles are posted on . Roflumilast cream was an effective and safe treatment for mild to moderate atopic dermatitis in adults and ...

Please provide your email address to receive an email when new articles are posted on . Regular use of bleach baths modestly improved atopic dermatitis severity among most patients with a good safety ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an AI-trained wearable sensor with vibrating feedback, the device significantly ...

An artificial intelligence (AI)-enabled hand sensor delivering closed-loop haptic feedback appeared to be an effective nonpharmacologic intervention to decrease nocturnal scratching in patients with ...

A wearable sensor that sticks onto the back of the hand and uses an artificial intelligence (AI) algorithm to monitor scratching activity when the wearer sleeps has been shown to reduce subconscious ...

Once-daily, steroid-free topical treatment designed to rapidly reduce itch and proactively support long term disease control Rapid and significant improvements in disease clearance with ZORYVE cream ...

The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for roflumilast cream 0.05%, a topical phosphodiesterase-4 inhibitor, for the treatment of ...

—In a small study, patients with mild atopic dermatitis were recruited to wear an artificial intelligence (AI)-enabled, hand-mounted sensor that triggers feedback designed to decrease nocturnal ...

After treatment, the mental health and sleep quality of mothers in the mild atopic dermatitis (AD) group improved significantly, while those of mothers in the moderate and severe AD groups only showed ...

BRIDGEWATER, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and ...